London, UK - Results of a randomized trial show a significant reduction in venous thromboembolism (VTE) events in stroke patients receiving the low-molecular-weight heparin (LMWH) enoxaparin (Lovenox, ...

A more selective risk-stratified approach to postpartum enoxaparin (Lovenox) thromboprophylaxis for venous thromboembolism (VTE) was linked to reduced rates of wound hematomas without increasing the ...

Boston, MA - Two new studies comparing the low-molecular-weight heparin (LMWH) enoxaparin (Lovenox® - Aventis) with the new synthetic pentasaccharide fondaparinux (Arixtra® - Sanofi-Synthelabo/Organon ...

(HealthDay News) — Once-daily enoxaparin is associated with fewer major bleeds than enoxaparin twice daily in patients with acute venous thromboembolism (VTE), according to a study published online in ...

Aspirin alone doesn’t seem to be enough to prevent symptomatic venous thromboembolism (VTE) in the months following total hip or knee replacement for osteoarthritis, results of the CRISTAL trial ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Patients who received either aspirin or enoxaparin for ...

In the Prevention of VTE in Acutely ill Patients, Rivaroxaban Compares Favorably with Enoxaparin but Does Not Show a Consistent Net Clinical Benefit MAGELLAN study meets primary efficacy endpoints of ...

Please provide your email address to receive an email when new articles are posted on . Treatment with rivaroxaban was more effective than enoxaparin for preventing venous thromboembolism during ...

Oral rivaroxaban (Xarelto; Bayer/Janssen) is superior to subcutaneous enoxaparin in preventing venous thromboembolism (VTE) without increasing bleeding in patients undergoing nonmajor orthopedic ...

In this study, no difference in the rate of CVC-related VTE was detected between patients receiving enoxaparin and patients receiving placebo. The dose of enoxaparin used in this study proved to be ...

Extended use of betrixaban beyond the usual period of parenteral prophylaxis with enoxaparin reduced venous thromboembolism (VTE) incidence among medically ill patients. WASHINGTON, DC—Extended use of ...